Definium Therapeutics, Inc. (DFTX) insider trading

By person

12 insiders · 19 transactions

123×

Robert Barrow holds 123 times base salary in stock. $80.93M of shares against $655.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Robert Barrow last reported holding, valued at $36.57, the price Common Shares was last bought or sold at on the open market here, on 25 Sep 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Robert Barrow

Chief Executive Officer

—

$3.98M (5) scheduled

−$3.98M

2,213,090

1.65%

$80.93M

+880.6%

Mark Sullivan

Chief Legal Officer

—

$1.45M (4) scheduled

−$1.45M

494,228

0.3678%

$18.07M

+848.1%

Daniel Karlin

Chief Medical Officer

—

$1.07M (4) scheduled

−$1.07M

792,846

0.5901%

$28.99M

+314.3%

Brandi Roberts

Chief Financial Officer

—

$259.17K (2) scheduled

−$259.17K

394,528

0.2936%

$14.43M

+42,877%

Matthew T. Wiley

Chief Commercial Officer

—

$242.36K (2) scheduled

−$242.36K

359,036

0.2672%

$13.13M

—

Carrie Liao

Chief Accounting Officer

—

144,923

0.1079%

$5.30M

+45.6%

Roger Crystal

Director

—

24,289

0.0181%

$888.25K

+23.8%

Suzanne Louise Bruhn

Director

—

24,289

0.0181%

$888.25K

+23.8%

Carol A Vallone

Director

—

22,296

0.0166%

$815.36K

+34.8%

Andreas Krebs

Director

—

21,402

0.0159%

$782.67K

+41.7%

David W Gryska

Director

—

19,900

0.0148%

$727.74K

+56.3%

Roger Adsett

Director

—

3,555

0.0026%

$130.01K

—

Definium Therapeutics, Inc.

What the insiders did Scheduled selling only

By person